Clinical trials · Minneapolis–St. Paul, MN
Cancer clinical trials in Minneapolis–St. Paul
We’re tracking 309 recruiting cancer studies with a site in or near Minneapolis–St. Paul — including Phase 1, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Minneapolis–St. Paul
- NCT05696626RecruitingPhase 3
Test a new pill plus abemaciclib versus standard therapy
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
Minneapolis, MinnesotaAges 18 years+ - NCT07166094RecruitingPhase 3
Rina-S vs standard therapy for advanced endometrial cancer
This trial tests a new drug called Rina-S (an antibody-drug conjugate) against standard treatments for advanced endometrial cancer that has returned after prior therapy. It may be an option if you have had at least 1 but no more than 3 prior treatments, including platinum chemo and immunotherapy.
Minneapolis, MinnesotaAges 18 years+ - NCT07281430Recruiting
HPV self-test for cervical cancer screening
This study tests if a self-collected sample for HPV testing works as well as standard colposcopy to prevent cervical cancer. If you've recently had an abnormal cervical cancer screening and need a colposcopy, this trial may be an option for you.
Minneapolis, MinnesotaAges 25 years+ - NCT06524544RecruitingPhase 3
Pembrolizumab and sacituzumab govitecan for advanced bladder cancer
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
Minneapolis, MinnesotaAges 18 years+ - NCT06498635RecruitingPhase 3
Immunotherapy after surgery for lung cancer with no remaining cancer
This trial tests whether giving immunotherapy (durvalumab) after surgery can help prevent lung cancer from coming back if you already had a complete response to chemo and immunotherapy before surgery. It is for people with early-stage non-small cell lung cancer who had no cancer left after treatment.
Minneapolis, MinnesotaAges 18 years+ - NCT07023289RecruitingPhase 2
Study of Telisotuzumab Adizutecan for ctDNA-Positive Colorectal Cancer
This trial tests a new drug, Telisotuzumab Adizutecan, given through a vein (infusion) alone or with standard treatments for people with colorectal cancer who have no visible tumors on scans but still have cancer DNA (ctDNA) in their blood after surgery and chemotherapy.
Minneapolis, MinnesotaAges 18 years+ - NCT07061964RecruitingPhase 2
Immunotherapy and radiation to save the bladder
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
Minneapolis, MinnesotaAges 18 years+ - NCT07218809RecruitingPhase 3
Comparison of AZD5335 vs standard treatments for advanced ovarian cancer
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
Minneapolis, MinnesotaAges 18 years+ - NCT07541573RecruitingPhase 1
GTB-5550 study for advanced solid tumors
This is an early-stage study testing a new drug called GTB-5550 in people with advanced cancers that have spread. The study aims to find the right dose and see if the drug helps shrink tumors.
Minneapolis, MinnesotaAges 18 years+ - NCT06731478RecruitingPhase 3
New drug combo for first treatment of HER2-positive stomach cancer
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
Minneapolis, MinnesotaAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Minneapolis, MinnesotaAges 18 years+ - NCT00539162Recruiting
CA-125 and other tests to check for early ovarian cancer risk
This study looks at how well a blood test called CA-125, along with other markers and checkups, can detect ovarian cancer early. It’s for women considered low risk who will do regular blood tests and possibly a vaginal ultrasound if results suggest it.
Minneapolis, MinnesotaAges 50–74 - NCT07062965RecruitingPhase 3
PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Minneapolis, MinnesotaAges 18 years+ - NCT06203600RecruitingPhase 2/Phase 3
Nivolumab plus standard treatment for advanced stomach or esophageal cancer
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
Minneapolis, MinnesotaAges 18 years+ - NCT06692426RecruitingPhase 1
Cell therapy for Duchenne muscular dystrophy
This trial tests a new cell-based treatment for Duchenne muscular dystrophy in adults who can no longer walk. The goal is to see if the therapy can help improve muscle function.
Minneapolis, MinnesotaAges 18 years+ - NCT06690775RecruitingPhase 2
Study of a new drug for platinum-resistant ovarian cancer
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
Minneapolis, MinnesotaAges 18 years+ - NCT05633654RecruitingPhase 3
Test drug combo versus standard care for triple-negative breast cancer
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
Minneapolis, MinnesotaAges 18 years+ - NCT06651580Recruiting
Gene study for kids with pancreas problems
This study collects samples like blood or tissue from children with pancreatitis to look for gene changes that might raise their risk. It helps doctors learn more about why some children get pancreas inflammation.
Minneapolis, MinnesotaAges Up to 17 years - NCT07493538RecruitingPhase 2
Blood stem cell transplant with lower-intensity chemo for blood cancers
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
Minneapolis, MinnesotaAges 2–75 - NCT05338658RecruitingPhase 1
Test drug PAT in adults with solid tumors
This Phase 1 study tests PAT in adults with solid tumor cancers who meet specific immune and health criteria. Because it’s an early safety-and-dosing study, it may help researchers learn whether PAT can be given safely and whether it shows any cancer activity in the right patients.
Minneapolis, MinnesotaAges 18 years+ - NCT07409272RecruitingPhase 3
Study of setidegrasib with chemo for pancreatic cancer
This trial tests a new drug called setidegrasib, given with two types of chemotherapy (mFOLFIRINOX or NALIRIFOX), for people whose pancreatic cancer has spread and has a specific genetic change called KRAS G12D. The goal is to see if adding setidegrasib helps control the cancer better than chemo alone.
Minneapolis, MinnesotaAges 18 years+ - NCT06792825RecruitingPhase 2
Tafasitamab with lenalidomide and rituximab for new lymphoma
This trial tests a combination of three drugs (tafasitamab, lenalidomide, and rituximab) for people with newly diagnosed follicular or marginal zone lymphoma who have not had treatment before. The goal is to see if this combination works well and is safe.
Minneapolis, MinnesotaAges 18 years+ - NCT03789721Recruiting
ALD registry study for patients and families in the U.S.
This study builds a national registry to better understand adrenoleukodystrophy (ALD) in patients and families. You may help researchers learn how ALD affects people over time and improve future care.
Minneapolis, MinnesotaAges Any age - NCT07005128RecruitingPhase 3
New Drug Combo for First-Line Extensive Small Cell Lung Cancer
This trial tests adding a new immunotherapy drug (tarlatamab) to the standard first-line chemo-immunotherapy for extensive-stage small cell lung cancer. It aims to see if the combination works better than the usual treatment alone.
Minneapolis, MinnesotaAges 18–99
Hear when a new Cancer trial opens near Minneapolis–St. Paul, MN
We’ll email you when one opens near Minneapolis–St. Paul, MN — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Minneapolis–St. Paul
Institutions with a site for the recruiting cancer studies listed above.
- University of Minnesota Masonic Cancer Center · 6 studies
- Allina Health Cancer Institute · 5 studies
- Minnesota Oncology Hematology · 5 studies
- Abbott-Northwestern Hospital · 4 studies
- Fairview Southdale Hospital · 4 studies
- Mercy Hospital · 4 studies
- Park Nicollet Clinic - Saint Louis Park · 4 studies
- Regions Hospital · 4 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in Minnesota.
Common questions
- Are there cancer clinical trials near Minneapolis–St. Paul?
- Yes. We're currently tracking 309 recruiting cancer studies with a site near Minneapolis–St. Paul, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Minneapolis–St. Paul?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Minneapolis–St. Paul to take part?
- Not necessarily. These studies have a site near Minneapolis–St. Paul, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Minneapolis–St. Paul regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.